诚达药业股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 诚达药业股份有限公司（以下简称"公司"）第六届董事会第一次会议于 2025 年 11 月 12 日在公司会议室以现场结合通讯的方式召开。根据《公司章程》 第一百一十八条第二款的规定"如遇紧急情况，需要尽快召开董事会临时会议的， 可以随时通过口头或者电话等方式发出会议通知，但召集人应作出说明"，本次 会议通知已于 2025 年 11 月 12 日通过口头和电话方式发出。会议召集人在本次 会议召开前就本次会议的特殊情况做出充分说明，并征得了全体董事的一致同意。 本次会议应出席董事 9 人，实际出席董事 9 人，其中董事卢瑾女士以通讯方式出 席会议，公司高级管理人员列席会议。本次会议由过半数以上的董事推举董事葛 建利女士主持。 本次会议的召集和召开符合有关法律、行政法规、部门规章和《公司章程》 的规定，形成的决议合法有效。 证券代码：301201 证券简称：诚达药业 公告编号：2025-045 二、董事会会议审议情况 会议经全体董事讨论后形成 ...

北京中伦文德（杭州）律师事务所 关于 诚达药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 北京中伦文德（杭州）律师事务所 地址：杭州市萧山区钱江世纪城广孚中心 1301 电话：0571-83685215 传真：0571-83685215 邮编：311200 北京中伦文德（杭州）律师事务所 法律意见书 北京中伦文德（杭州）律师事务所 关于诚达药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：诚达药业股份有限公司 北京中伦文德（杭州）律师事务所（以下称"本所"）接受诚达药业股份有 限公司（以下称"公司"）的委托，指派律师出席公司 2025 年第二次临时股东 大会（以下称"本次股东会"），本所律师根据《中华人民共和国公司法》（以 下称"《公司法》"）、《中华人民共和国证券法》（以下称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所上 市公司股东会网络投票实施细则》等法律、法规和规范性法律文件以及《诚达药 业股份有限公司章程》（以下称"《公司章程》"）的规定，就公司本次股东会 的召集召开程序、出席会议人员的资格、召集人的资格、表决程序和表决结 ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-044 诚达药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2025 年 11 月 12 日（星期三）下午 14：00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 11 月 12 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为：2025 年 11 月 12 日 9:15—15:00。 2、召开地点：浙江省嘉兴市嘉善县惠民街道黄河路 36 号诚达药业股份有限 公司会议室。 3、召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 4、召集人：董事会 5、主持人：董事长葛建利女士 本次股东大会采用现场投票与网络投票相结合的表决方式对以下议案进行 ...

Market Overview - Technology stocks experienced a collective pullback, with indices showing a slight V-shaped recovery [3] - The biodiesel sector saw significant gains, with stocks like Shanhigh Environmental and Jiaao Environmental hitting the daily limit [3] - Gene editing stocks surged, with companies such as Nanjing Xinbai and Jimin Health reaching their daily limits [3] - Oil service stocks also performed well, with companies like Zhun Oil and Shandong Molong hitting the daily limit [3] - The satellite internet sector saw a late-stage rally, with Shanghai Huguang and Shanghai Gangwan both experiencing sharp increases [3] Banking Sector - The banking sector showed resilience amidst the overall market decline, with major banks like Agricultural Bank of China leading the way [5] - Agricultural Bank of China saw a significant increase of 3.49%, reaching a market capitalization of over 3 trillion, solidifying its position as the second-largest bank globally [6] Satellite Internet - The satellite internet sector rebounded sharply in the late trading session, with notable gains from companies like Aerospace Zhizhuang and China Satellite [10] - The catalyst for this rally was the announcement of a new, cheaper Starlink home package by SpaceX, priced at $40 per month [10] Company-Specific Developments - Xingsen Technology experienced a rise of 6% after rumors of a partnership with Nvidia surfaced, although these claims were later disputed [12][13] - Daily Interaction saw a volatile trading session, initially declining but then surging over 10% due to speculation around a new product release related to DeepSeek [19]

Core Insights - The medical services sector experienced a slight increase of 0.14% on November 12, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 35.90, up 6.34% with a trading volume of 107,700 shares and a transaction value of 386 million [1] - Innovative Medical (002173) closed at 23.47, up 5.67% with a trading volume of 805,700 shares and a transaction value of 189.6 million [1] - ST Zhongzhu (600568) closed at 2.08, up 5.05% with a trading volume of 391,000 shares [1] - Other notable gainers include ST Biological (000504) up 5.00%, Sunshine Nuohe (688621) up 4.49%, and Bid Medical (688073) up 3.65% [1] Fund Flow Analysis - The medical services sector saw a net inflow of 604 million from institutional investors, while retail investors experienced a net outflow of 615 million [2] - Major stocks with significant net inflows include WuXi AppTec (603259) with 76.27 million and Innovative Medical (002173) with 57.21 million [3] - Conversely, Sunshine Nuohe (688621) experienced a net outflow of 98.24 million from institutional investors [3]

Group 1 - The immunotherapy sector is experiencing a strong rebound, with companies like Zhongyuan Qihuo and Kaineng Health hitting the daily limit up [1] - Other companies in the sector, such as Jimin Health, Guanhao Bio, Chengda Pharmaceutical, Zexing Pharmaceutical, and Heyuan Bio, are also showing significant gains [1]

Group 1 - The cell immunotherapy sector experienced a significant rally in the afternoon, with Kaineng Health hitting a 20% limit up, and Jimin Health, Zhongyuan Qihe, and Nanjing Xinbai also previously reaching their limit up [1] - Sanyuan Gene saw an increase of over 10%, while Chengda Pharmaceutical and Sunshine Nuohe also followed the upward trend [1] - A recent research paper published in the journal Nature Biotechnology indicates that low-intensity ultrasound treatment can eliminate neurotoxic debris in the brains of mice induced with hemorrhagic stroke [1]

Core Insights - On November 11, Chengda Pharmaceutical experienced a decline of 0.32% with a trading volume of 184 million yuan, indicating a slight downturn in market performance [1] - The company reported a financing buy-in of 16.04 million yuan and a financing repayment of 17.94 million yuan on the same day, resulting in a net financing outflow of 1.89 million yuan [1] - As of November 11, the total margin balance for Chengda Pharmaceutical stood at 244 million yuan, which accounts for 4.67% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Financing and Margin Data - Chengda Pharmaceutical's financing buy-in on November 11 was 16.04 million yuan, with a current financing balance of 244 million yuan, which is above the 90th percentile of the past year [1] - The company had no short-selling activity on November 11, with a short-selling balance of 0 yuan, placing it below the 50th percentile of the past year [1] Company Overview - Chengda Pharmaceutical, established on March 25, 1999, and listed on January 20, 2022, is located in Jiaxing, Zhejiang Province [1] - The company's main business includes the development, production, and sales of key pharmaceutical intermediates, CDMO services, and L-carnitine series products [1] - The revenue composition of the company is as follows: 60.66% from self-sales products, 38.90% from customized products and services, and 0.44% from other sources [1] Financial Performance - As of September 30, the number of shareholders for Chengda Pharmaceutical was 12,700, a decrease of 8.58% from the previous period, while the average circulating shares per person increased by 36.16% to 8,577 shares [2] - For the period from January to September 2025, the company achieved a revenue of 285 million yuan, representing a year-on-year growth of 16.95%, while the net profit attributable to shareholders decreased by 58.47% to 16.77 million yuan [2] Dividend Information - Since its A-share listing, Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends, with 89.62 million yuan distributed over the past three years [3]

Core Insights - The medical services sector experienced a rise of 0.89% on November 10, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.87, with an increase of 8.94% and a trading volume of 99,000 shares, amounting to a transaction value of 330 million [1] - Tongce Medical (600763) saw a closing price of 44.51, up 5.00%, with a trading volume of 174,500 shares and a transaction value of 769 million [1] - Puri Eye Hospital (301239) closed at 38.73, up 4.96%, with a trading volume of 38,500 shares and a transaction value of 148 million [1] - Other notable performers include Hite Bio (300683) with a 4.85% increase, and Aier Eye Hospital (300015) with a 3.40% increase [1] Capital Flow Analysis - The medical services sector saw a net outflow of 185 million from institutional investors, while retail investors contributed a net inflow of 84.71 million [2] - Major stocks like Aier Eye Hospital (300015) experienced a net inflow of 300 million from institutional investors, despite a significant outflow from retail investors [3] - Tongce Medical (600763) had a net inflow of 115 million from institutional investors, but also faced outflows from retail investors [3]

证券代码：301201 证券简称：诚达药业 公告编号：2025-043 诚达药业股份有限公司 关于召开 2025 年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于2025年10月24日召开第五届董事会第十 四次会议审议通过《关于召开2025年第二次临时股东大会的议案》，同意于2025年11月12日 （星期三）下午14点召开2025年第二次临时股东大会。现将本次股东大会的召开事项提示如 下： 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）在股权登记日持有公司已发行有表决权股份的股东或其代理人； 截至 2025 年 11 月 5 日下午收市时在中国结算深圳分公司登记在册的公司全体已发行 ...